Display options
Cite
Lutz M, von Ingersleben N, Lambers M, et al. Osteopontin predicts clinical outcome in patients after treatment of severe aortic stenosis with transcatheter aortic valve implantation (TAVI). Open Heart. 2017;4(2):e000633doi: 10.1136/openhrt-2017-000633.
Lutz, M., von Ingersleben, N., Lambers, M., Rosenberg, M., Freitag-Wolf, S., Dempfle, A., Lutter, G., Frank, J., Bramlage, P., Frey, N., & Frank, D. (2017). Osteopontin predicts clinical outcome in patients after treatment of severe aortic stenosis with transcatheter aortic valve implantation (TAVI). Open heart, 4(2), e000633. https://doi.org/10.1136/openhrt-2017-000633
Lutz, Matthias, et al. "Osteopontin predicts clinical outcome in patients after treatment of severe aortic stenosis with transcatheter aortic valve implantation (TAVI)." Open heart vol. 4,2 (2017): e000633. doi: https://doi.org/10.1136/openhrt-2017-000633
Lutz M, von Ingersleben N, Lambers M, Rosenberg M, Freitag-Wolf S, Dempfle A, Lutter G, Frank J, Bramlage P, Frey N, Frank D. Osteopontin predicts clinical outcome in patients after treatment of severe aortic stenosis with transcatheter aortic valve implantation (TAVI). Open Heart. 2017 Jun 10;4(2):e000633. doi: 10.1136/openhrt-2017-000633. eCollection 2017. PMID: 28761684; PMCID: PMC5515168.
Copy Download .nbib Format: NLM
Share it on

Open Heart. 2017 Jun 10;4(2):e000633. doi: 10.1136/openhrt-2017-000633. eCollection 2017.

Osteopontin predicts clinical outcome in patients after treatment of severe aortic stenosis with transcatheter aortic valve implantation (TAVI).

Open heart

Matthias Lutz, Nora von Ingersleben, Moritz Lambers, Mark Rosenberg, Sandra Freitag-Wolf, Astrid Dempfle, Georg Lutter, Johanne Frank, Peter Bramlage, Norbert Frey, Derk Frank

Affiliations

  1. Department of Internal Medicine III (Cardiology and Angiology), University Hospital Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany.
  2. German Centre for Cardiovascular Research, DZHK Partner Site Hamburg/Kiel/Lübeck, Kiel, Germany.
  3. Institute of Medical Informatics and Statistics, Christian-Albrechts University of Kiel, Kiel, Germany.
  4. Department for Cardiovascular Surgery, University Hospital Schleswig-Holstein, Kiel, Germany.
  5. Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany.

PMID: 28761684 PMCID: PMC5515168 DOI: 10.1136/openhrt-2017-000633

Abstract

OBJECTIVE: Osteopontin (OPN) is an extracellular matrix protein that plays an integral role in myocardial remodelling and has previously been shown to be a valuable biomarker in cardiovascular disease. Because of the concentric myocardial hypertrophy associated with severe, symptomatic aortic stenosis (AS), we hypothesised that OPN expression may have a prognostic value in patients undergoing transcatheter aortic valve implantation (TAVI).

METHODS: We prospectively included 217 patients undergoing TAVI between February 2011 and December 2013 with a median follow-up of 349 days. Twenty healthy individuals from the same age range free from structural heart disease served as controls. The primary endpoint for the analysis was survival time.

RESULTS: Median preprocedural OPN levels (675 ng/mL; IQR 488.5-990.5 ng/mL) were significantly higher in patients with severe aortic valve stenosis compared with healthy controls (386 ng/mL; IQR 324.5-458, p<0.001). Patients with increased OPN values showed at baseline a decreased 6 min walk test performance, increased rates of atrial arrhythmia, and an increased risk of death during follow-up (HR 2.2; 95% CI 1.3 to 3.5 for the comparison of the highest vs lowest OPN quartile). Multiple Cox regression analysis demonstrated that OPN improves the prediction of an adverse prognosis further than N-terminal probrain natriuretic peptide.

CONCLUSIONS: OPN levels at baseline are associated with adverse outcomes in patients with severe, symptomatic AS undergoing TAVI.

Keywords: NTproBNP; aortic stenosis; death; osteopontin; transcatheter aortic valve intervention

Conflict of interest statement

Competing interests: None declared.

References

  1. Eur Heart J. 2015 Aug 21;36(32):2184-96 - PubMed
  2. Circulation. 2010 Jul 6;122(1):62-9 - PubMed
  3. Hypertension. 1999 Feb;33(2):663-70 - PubMed
  4. Clin Cardiol. 2013 Apr;36(4):228-34 - PubMed
  5. Int J Cardiol. 2013 Nov 5;169(3):e38-9 - PubMed
  6. Eur J Cardiothorac Surg. 2012 Apr;41(4):734-44; discussion 744-5 - PubMed
  7. Circ Heart Fail. 2008 May;1(1):43-9 - PubMed
  8. Eur J Heart Fail. 2015 Sep;17(9):945-55 - PubMed
  9. Eur Heart J. 2015 Feb 7;36(6):328-30 - PubMed
  10. J Am Coll Cardiol. 2004 May 5;43(9):1698-705 - PubMed
  11. Eur Heart J. 2003 May;24(9):881-2 - PubMed
  12. Circulation. 1997 Nov 4;96(9):3063-71 - PubMed
  13. Cardiovasc Ther. 2016 Dec;34(6):385-396 - PubMed
  14. Heart. 2013 Sep;99(17):1261-6 - PubMed
  15. JACC Cardiovasc Interv. 2013 May;6(5):487-96 - PubMed
  16. Mol Cell Biochem. 2007 Jun;300(1-2):1-7 - PubMed
  17. Eur Heart J. 2003 Jul;24(13):1231-43 - PubMed
  18. Eur J Cardiothorac Surg. 2010 Aug;38(2):119-27 - PubMed
  19. Physiol Rev. 2012 Apr;92(2):635-88 - PubMed
  20. Ann Thorac Surg. 2009 Jul;88(1 Suppl):S23-42 - PubMed
  21. Am Heart J. 2010 Feb;159(2):323-9 - PubMed
  22. Arch Cardiovasc Dis. 2012 Mar;105(3):141-5 - PubMed
  23. N Engl J Med. 2016 Jul 28;375(4):335-44 - PubMed
  24. J Am Coll Cardiol. 2013 Sep 3;62(10):869-77 - PubMed
  25. Circ Res. 2008 Feb 15;102(3):319-27 - PubMed
  26. Lancet. 2006 Sep 16;368(9540):1005-11 - PubMed
  27. Hypertension. 2004 Jun;43(6):1195-201 - PubMed

Publication Types